Summary: Nitric oxide (NO) is a ubiquitous molecule involved in multiple cellular functions. Inappropriate production of NO may lead to disease states. To date, pharmacologically active compounds that release NO within the body, such as organic nitrates, have been used as therapeutic agents, but their efficacy is significantly limited by rapid NO release, toxicity and induction of tolerance. Therefore, novel NO donors with better pharmacological and phamacokinetic properties are highly desirable. The S-nitrosothiol fraction in plasma is largely composed of S-nitrosylated human serum albumin (SNO-HSA) and that is why we are testing whether this albumin form can be used as a NO traffic protein. We have found that oleate and other endogenous ligands increase SNO-HSA formation in vitro. The cytoprotective effect of SNO-HSA in a ischemia/reperfusion model and its antiapoptotic effect on HepG2 cells treated with anti-Fas antibody were pronounced and could be enhanced by binding of oleate. The enhancement of S-transnitrosation to the HepG2 cells could be completely blocked by filipin III, a caveolae inhibitor. These findings indicate that a clinical application of SNO-HSA is expected as potent NO supplementary therapy and that fatty acids may serve as novel types of mediators for S-transnitrosation.
Introduction
Depending on the location of its release, nitric oxide (NO) serves a wide range of biological functions. For example, low concentrations of NO produced by constitutive NO synthase (cNOS) isoforms have several cytoprotective effects, such as regulation of local blood flow as an endothelium-derived relaxing factor, 12) inhibition of platelet aggregation, 28) attenuation of neutrophil adherence, 29) removal of superoxides, 30) and inhibition of superoxide anion production by neutrophils. 31) Defects of NO production can lead to many cardiovascular abnormalities such as essential hypertension, stroke, atherosclerosis and ischemia/reperfusion injury. 32) Therefore, replacement of or supplementing endogenous NO production by exogenously administered NO is an important and effective treatment for cardiovascular diseases. However, NO therapy still has some problems that should be overcome, such as the following.
First, administration of NO gas has limited utility, partly because of its short half-life in vivo (¿0.1 s). 33) Therefore, pharmacologically active compounds that can release NO or lead to its formation in the body have been synthesized. Organic nitrates and nitrite esters have been used for many years to treat patients with ischemic heart disease. However, there are well-known side-effects and limitations to these NO donors, including potentially adverse hemodynamic effects, drug tolerance, lack of selectivity and limited bioavailability. 34, 35) Thus, it is essential to develop reliable NO donors with better pharmacologi-cal and pharmacokinetic parameters.
Secondly, it is important to be able to control reaction selectivity and dose of the NO donor against reactive oxygen species such as in NO therapy in inflammatory diseases. A high concentration of NO produced by inducible NOS (iNOS) is protective against bacterial infection in inflammatory processes, but too much NO will induce apoptosis and cellular damage. 1, 8, 36, 37) The latter effect is due to the formation of peroxynitrite (ONOO -), the reaction product of the interaction between superoxide (O2 -) and NO, a potent proinflammatory nitroxide implicated in acute and chronic inflammatory conditions of many etiologies. [38] [39] [40] [41] In addition, tissue injury and inflammation often accompany rapid development of hypersensitivity to noxious and nonnoxious stimuli (hyperalgesia and allodynia, respectively). In fact, sodium nitroprusside (SNP), which has been parenterally administered for the treatment of hypertension and heart failure, also induces an increase in the vascular production of superoxide leading to the formation of ONOO -, which is associated with cytotoxic effects of SNP. 42, 43) Thirdly, local application of NO may be a very effective and safe form of NO therapy. To develop a method for the targeted delivery of NO, several groups of researchers have synthesized NO donors that hopefully can release NO selectively at a target site. For example, V-PYRRO/NO and 2-(acetyloxy) benzoic acid 3-(nitrooxymethyl) phenyl ester (NCX-1000) can selectively release NO in the liver. NO release from V-PYRRO/NO is mediated by cytochrome P450 which removes the vinyl group of the drug to generate free PYRRO/NO ion. [44] [45] [46] NCX-1000 is a prototype of a family of NO releasing derivatives of ursodeoxycholic acid. The two compounds are selectively metabolized in the liver and biologically active NO enters the liver microcirculation with no detectable effect on systemic circulation. 47) However, these NO donors have not yet been applied in clinical situations because the reaction mechanisms are not yet fully clarified. Thus, although NO release from V-PYRRO/NO is mediated by cytochrome P450, the isoform of cytochrome P450 catalyzing the process has not been identified. The enzyme that mediates NO release from NCX-1000 is still unknown. The enzymes that mediate NO release from V-PYRRO/NO and NCX-1000 must be identified in order to optimize their therapeutic efficacy. 48) In our search for a reliable and safe NO donor, we have followed a different approach, namely to examine the possibility of using a NO-traffic protein. By a NOtraffic protein is meant a protein with i) high efficiency of S-nitrosylation, ii) high stability of the S-nitroso form in the circulation and iii) high efficiency of S-transnitrosation into cells which need NO. As a candidate in this respect we focus on human serum albumin (HSA), because HSA is the most abundant plasma protein (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) g/L) and because endogenous S-nitrosothiols in human plasma is largely associated with HSA. 49) S-nitrosylated HSA (SNO-HSA) is significantly more stable than low molecular weight S-nitrosothiols. 48) Also others have attempted to produce NO delivery systems using a NO-albumin conjugate. Marks et al. 50) and Ewing et al. 51) have synthesized a macromolecular S-nitrosothiol, poly SNO-BSA, in which several S-nitrosothiols are formed in bovine serum albumin (BSA) after reduction of the proteins disulfide bonds. Independently, Beak et al. have developed a macromolecular NONOate, diazeniumdiolated BSA, in which several NONOate moieties are conjugated to native BSA. 52) In a porcine coronary angioplasty model, the two BSA-forms, poly SNO-BSA and diazeniumdiolated BSA, were applied locally to a site of vascular injury and showed high retention at the administration site and reduced platelet attachment and activation. These effects were due to high binding of the modified albumins to the injured vessel.
In the development of targeted NO delivery systems for intravenous use, tissue distribution characteristics of the NO-carrier conjugate should be evaluated in vivo in order to identify the various obstacles to targeted delivery, such as extensive uptake by mononuclear phagocyte systems and rapid loss by glomerular filtration. Katsumi et al. have examined the pharmacokinetic properties of SNO-BSA. The results showed that serum albumin is a promising carrier to control pharmacokinetic properties of NO after intravenous injection, because S-nitrosylated albumin shows a relatively high retention in the blood circulation after intravenous injection into mice. However, targeted NO delivery after intravenous injection using a macromolecular carrier has not been successfully achieved so far. 53) To achieve targeted NO delivery from SNO-HSA after intravenous injection, we need to understand the different functions and structure of HSA and its biological fate in detail. Therefore, we have recently examined the relationship between S-nitrosylation and reversible binding of ligands to HSA. This review summarizes the effects of endogenous ligands on Snitrosylation and S-transnitrosation of HSA both in vitro and in biological systems.
Structure and S-Ritrosylation of HSA
HSA is a single-chain, non-glycosylated protein with a molecular weight of 66.5 kDa. It is synthesized in and secreted from liver cells. The polypeptide organizes to form a heart-shaped protein with approximately 67% ahelix but no b-sheet.
54)
It is composed of three homologous domains (I-III) each of which can be subdivided into subdomains (A and B) with distinct helical folding patterns connected by flexible loops (Fig. 1) . All but one (Cys-34) of the 35 cysteine residues are involved in the formation of stabilizing disulfide bonds. In the circulation, the protein has an average half-life of 19 days, and (1)) and the high-affinity binding site (Cu 2＋ (1)) and a secondary binding site for Cu 2＋ (Cu 2＋ (2)) are indicated. Very recently, crystallographic analysis of HSA complexed with BR has shown, that the ligand is bound with high affinity in subdomain IB rather than in subdomain IIA.
70) The subdivision of HSA into domains (I-III) and subdomains (A and B) is given. The structure was simulated on the basis of X-ray crystallographic data for HSA-AO (PDB ID code 1gni) and modified with the use of Rasmol (downloaded from http://www.openrasmol.org).
Fig. 2. Chemical reactions of NOC-7 and GS-NO with R-SH
normally about half of the Cys-34 residues are freely accessible; i.e., they are not oxidized or involved in ligand binding and represent the largest fraction of free thiols in the blood. 54) In the blood, HSA serves, among other things, as a transport and depot protein for numerous endogenous and exogenous compounds. 54, 55) Therefore, we have studied, as a first step, the effects of the strongly bound ligands, oleate (OA) (C18:1), bilirubin (BR) and Cu 2＋ and the weakly bound ligands, L-tryptophan, progesterone, ascorbate, Zn 2＋ and Fe 2＋ on in vitro S-nitrosylation of HSA by S-nitrosoglutathione (GS-NO) and 1-hydroxy-2-oxo-3-(N-3-methyl-aminopropyl)-3-methyl-3?-triazene (NOC-7). We also studied the effects of the strongly bound ligands on S-nitrosylation of HSA in a biological system using stimulated RAW264.7 cells.
S-Nitrosylation of Mercaptalbumin with Bound Ligands
HSA purified from serum sossesses bound endogenous ligands, in particular fatty acids and perhaps also exogenous ligands. Any effect of these ligands on the Snitrosylation of HSA was examined by incubating nondefatted and charcoal-treated albumin, with GS-NO. The S-nitroso moiety of the former preparation was significantly higher ( Pº0.01) than that of the latter. 56) Thus, the presence of ligands greatly enhance the efficiency of S-nitrosylation. In order to identify ligands of importance for S-nitrosylation, individual ligands were added to HSA previously delipidated by charcoal and dialyzed extensively against deionized water. In these experiments, two kinds of S-nitrosylating agents were used, namely GS-NO which S-transnitrosates via NO ＋ , and NOC-7 which S- nitrosylates mainly via NO and N2O3 (Fig. 2) . The results obtained with equimolar amounts of protein and ligand are indicated in Table 1 . It can be seen that OA and BR enhance the efficiency of GS-NO, but not that of NOC-7, whereas Cu 2＋ increases S-nitrosylation by NOC-7 but not that caused by GS-NO. In contrast, no significant effect was observed when adding L-tryptophan, progesterone, ascorbate, (CH3COO)2Zn or FeCl2. We studied in more detail the positive effects of OA, BR and Cu
2＋
, which bind to different high-affinity sites of HSA (Fig. 1) .
Effect of AO binding: We investigated the effect of increasing OA on S-nitrosylation of HSA by GS-NO in more detail. Increment was found to be dose-dependent up to a OA:HSA molar ratio of 3; increasing the molar ratio further to 4 or 5 did not result in additional Snitrosylation. Because OA does not bind to Cys-34 ( Fig.  1) , the effect observed most probably is due to bindinginduced conformational changes of HSA making Cys-34 more accessible to GS-NO. 56) This proposal is supported by the finding that OA binding results in an almost linear increment in binding of the test-compound 5,5?-dithiobis -2-nitrobenzoic acid (DTNB) to Cys-34.
56)
The proposal is also supported by crystal structure analysis. [57] [58] [59] According to analysis, the reactive SH group of Cys-34 is located in a crevice on the surface of HSA. Binding of OA induces conformational changes in the protein, leading to a slight opening of the interface between the two halves of the albumin molecule (subdomains IA-IIA and IIB-IIIB, respectively) and a rotation of domain I. These structural changes result in greater opening of the crevice that contains Cys-34 rendering the SH-group of Cys-34.
58)
Effect of BR binding: The effect of BR binding on S-nitrosylation by GS-NO was also studied at different molar ratios of ligand to protein. Binding of 1 mol of BR resulted in significantly higher S-nitrosylation ( Pº0.01); increasing the molar ratio to 3 or 5 did not cause additional S-nitrosylation. Thus, only high-affinity BR binding increases S-nitrosylation. Because this kind of binding takes place in another region of HSA to a greater extent than that possessing Cys-34 ( Fig. 1) , the improving effect must be due to conformation change in the protein related to accommodation of the large BR molecule. In contrast to GS-NO, high-affinity binding of BR does not influence S-nitrosylation by NOC-7 ( Table 1) . To test whether this lack of effect could be caused by interaction between NO and HSA-bound BR, we performed spectrophotometric experiments. The experiments showed that exposure of HSA-BR to NOC-7, but not to GS-NO, resulted in fast decrease of absorbancy at 470 nm (representing lmax for HSA-BR) and concomitant and pronounced increase at 650 nm (representing lmax for HSA-biliverdin). Therefore, the following reaction seems to take place: ( -. Thus, lack of effect of BR is due to its conversion to biliverdin (BV), and neither ligand nor NO2
-formed improves S-nitrosylation. Effect of Cu binds with a very high affinity to a specific site in the N-terminal region of HSA, and His-3 is an essential element at that site 54) ( Fig. 1) . To test whether high-affinity binding of Cu
2＋
, which takes place at a distance from Cys-34, is responsible for the improving effect of NOC-7, or whether the effect is caused by other means, e.g. secondary binding, we mutated His-3 for an alanine. Positive effect of Cu binding is most probably caused by conformational change induced in the HSA molecule, which renders the SH-group of Cys-34 more reactive. Such a mechanism seems supported by the results of Zhang and Wilcox. 60) These authors, using isothermal titration calorimetry and different spectroscopic techniques, found evidence for interaction between the first Cu does not affect the accessibility of Cys-34. 56) In contrast to the above studies, Stubauer et al. 61) found no effect of high-affinity bound Cu 2＋ on RS-NO formation. RS-NO formation was only initiated, when that binding site was saturated and the authors proposed S-nitrosylation of Cys-34 when Cu 2＋ binds with a low affinity to the same residue. However, they used BSA and NO gas in their studies.
Experiments with a cell line: To study S-nitrosylation of HSA in a biological system, we investigated the process caused by the murine macrophage cell line RAW264.7. The cell line had been activated by interferon-g and lipopolysaccharide for expressing inducible facilitate S-nitrosylation of Cys-34 in HSA. A common aspect to the binding of the three ligands is that they all bind with high affinity to the same part of HSA as that housing Cys-34, namely domain I (see legends to Fig. 1) . The improving effect of ligand binding was observed in vitro and in a biological system, but depended on the NO donor.
Effect of Fatty Acids on S-Transnitrosation of HSA
In the following, the effect of endogenous fatty acids on S-transnitrosation from SNO-HSA is described. The effect was studied using an animal model and cultured cells. Again, OA was used as a representative for the fatty acids, because quantitatively it is the most important fatty acid in human depot fat and because it is a major contributor to the albumin-bound fatty acids. As in the studies on S-nitrosylation, we used OA:HSA molar ratios up to 5:1. This was done for investigating the potential effect of physiological and pathological fatty acid concentrations. Thus, HSA usually carries a total amount of 1-2 molar equivalents of fatty acids. However, this value can rise to 4 or more after maximal exercise or other adrenergic stimulation.
54)
Cytoprotection against ischemia/reperfusion liver injury in rats: To determine the effect of OA binding on S-transnitrosation from SNO-HSA in vivo, we used an ischemia/reperfusion liver injury model. 62) To evaluate liver injury, the extracellular release of the liver enzymes asparatate aminotransferase (AST) and alanine aminotransferase (ALT) was measured via plasma enzyme values. Injecting HSA, OA or HSA-OA into the portal vein immediately after reperfusion had no effect on plasma concentrations of AST and ALT. But administration of SNO-HSA diminished, to a significant extent ( Pº0.01), the enzyme concentrations measured at 60 min and 120 min. The protection of the liver cells by SNO-HSA was more pronounced, if the protein also carried OA. The effect of OA on SNO-HSA-mediated cytoprotection appeared to depend on OA content; e.g., the binding of 5 mol OA had more pronounced effect than binding of 3 mol. We also found that caprylate (C8:0), a short-chain and saturated fatty acid, potentiated the cytoprotective effect of SNO-HSA. However, improved effect of caprylate was slightly less than that of OA.
The pharmacokinetic characteristics of SNO-HSA have been studied in mice. The study showed that binding of as much as 5 mol of OA per mol of SNO-HSA does not effect neither the protein forms plasma half-life nor its uptake by liver, kidney or spleen ( Table 2 ).
62)
The advantageous effects of fatty acids on cytoprotection found in the ischemia/reperfusion model may involve multiple mechanisms, including maintenance of tissue blood flow, induction of heme oxygenase-1 (a cytoprotective enzyme), suppression of neutrophil infiltration and reduction of apoptosis. 63) Therefore, we investigated the effect of fatty acid binding in a simpler system, a cell line.
Cytoprotection of HepG2 cells exposed to antiFas antibody: NO and related species have been reported able to induce both antiapoptotic and proapoptotic response in cells, the type of response depending on the concentration of NO donor and type of cell and apoptosis-inducing reagent. 64) We have examined the influence of OA binding on the antiapoptotic effect of SNO-HSA on HepG2 cells treated with anti-Fas antibody. The presence of HSA, with or without bound OA, or OA alone had no effect on induced apoptosis. In contrast, addition of SNO-HSA resulted in concentration-dependent protection of the cells. This protection was greatly increased by binding 5 mol of OA per mol of SNO-HSA. Thus, fatty acid binding also improves the cytoprotective effect of SNO-HSA in an in vitro system.
The above findings clearly show that HepG2 cells Stransnitrosate to SNO-HSA. This aspect we have studied in a direct way, namely by measuring the concentration of SNO-HSA. We found that the presence of the cells caused decrease in SNO-HSA, and that decrease was faster and quantitatively more pronounced in the presence of OA. The effect increased with OA concentration: from 1:1 to 3:1 to 5:1 molar ratios. The OAmediated promotion of SNO-HSA decay can be explained by increased accessibility to the S-nitroso moiety of HSA and/or by an intensified interaction between SNO-HSA and cell surface thiols.
We examined whether the improving effect of OA binding on S-transnitrosation is unique for that fatty acid, or whether the effect can also be exerted by a mixture of Results are expressed as means±SEM (n＝3-4). Fig. 3 . S -transnitrosation of SNO-HSA made from HSA isolated from hemodialytic patients after dialysis by HepG2 cells HSA samples were isolated by polyethylene glycol fractionation of blood plasma followed by chromatography on a Blue Sepharose column. 62) The HSA samples were S-nitrosylated using isoamyl nitrite. SNO-HSA and HepG2 cells were incubated for different periods of time and T 1/2 for S-transnitrosation of the different SNO-HSA samples were determined. Data represent means of four experiments.
endogenous fatty acids. We used HSA preparations isolated from hemodialysis patients, because such treatment increases fatty acid concentrations in the blood ( Table  3) . S-transnitrosation was quantified by determining the time necessary for HepG2 cells to cause halving of the SNO-HSA concentration (T1/2 of SNO-HSA). As seen in Figure 3 , there is good linear correlation between T1/2 and the amount of fatty acid bound to SNO-HSA. Thus, in addition to OA, a mixture of endogenous fatty acids facilitates the decay of SNO-HSA by HepG2 cells. This finding has biological and clinical implications, because the plasma concentrations of non-esterified fatty acids can be increased in a number of situations. In addition to hemodialysis, increase in fatty acids is seen in connection with exercise and other adrenergic stimulation and in pathological conditions such as the metabolic syndrome and diabetes mellitus.
S-Transnitrosation of SNO-HSA by GSH: Kinetic aspects of S-transnitrosation of SNO-HSA have also been studied in vitro by using glutathione (GSH) as a NO-acceptor. The amount of GS-NO formed after 30 min incubation with SNO-HSA and decay in SNO-HSA, was more pronounced when OA was bound to SNO-HSA. Surprisingly, the effect was the same, whether SNO-HSA bound 1, 3 or 5 mol of OA per mol of protein. Thus possibly, only protein conformational changes caused by binding of the first OA molecule are essential for S-transnitrosation to GSH.
NO Uptake of HepG2 Cells
As mentioned above, fatty acid binding accelerates SNO-HSA decomposition by HepG2 cells. We investigated whether this decomposition is accompanied by NO uptake by the cells using intracellular DAF-FM DA fluorescence (fluorescence of diaminofluorescein-FM diacetate). Intracellular NO concentration increased with incubation time and with increasing OA/SNO-HSA molar ratios. To clarify the S-transnitrosation properties of a saturated fatty acid, we tested the effect of stearate (C18:0) on NO uptake by HepG2 cells. Stearate had an effect on the S-transnitrosation of SNO-HSA, which is very similar to that of OA.
Fatty acid-induced increment in the transfer of NO from SNO-HSA into the hepatocytes is completely blocked by the addition of filipin III. However, a basal mechanism, not affected by filipin III addition, slows the transfer of small amounts of NO or modifications thereof (e.g. NO ＋ ). Both systems may involve a membrane protein and operate by transferring NO ＋ from one thiol to another.
We examined whether NO uptake involves contact between albumin and the cell membrane or components thereof using FITC-fluorescence (fluorescence of fluorescein isothiocyanate). SNO-HSA was labeled with FITC and interaction with the HepG2 cells was analyzed by fluorescence microscopy. 62) FITC-SNO-HSA was found to bind to the cells, and that binding increased in a dosedependent manner by cobinding of OA. Similar results were obtained with HSA that was not S-transnitrosylated. HSA binding to HepG2 cells is thus not affected by Stransnitrosation. Adding filipin III had no effect on the protein-cell interaction. Thus, OA is proposed to enhance the interaction between SNO-HSA and HepG2 cells. troduces conformational change in HSA that renders the SH-group, without or with S-nitrosylation, more accessible. Fatty acid binding also facilitates the binding of albumin to a receptor on hepatocytes, perhaps the albumin binding adaptor protein gp60. 65) When bound to the receptor, SNO-HSA-OA S-transnitrosates to HepG2 cells via two (or more) systems. Because OA-induced transnitrosation is completely blocked by filipin III, an inhibitor of caveolae, 66) it is proposed that caveolae are important for this type of S-transnitrosation. These findings strongly suggest that OA and NO of SNO-HSA-OA are transported by caveolae-associated proteins. Further studies are needed to identify and clarify the mechanism for the caveolae-associated proteins.
Conclusion
It is widely assumed that S-transnitrosation from SNO-HSA to cells takes place solely or mainly via low molecular weight thiols. [67] [68] [69] However, it should be noted that all the experiments with HepG2 cells were performed in the absence of GSH and other low molecular weight thiols.
Thus, fatty acid binding improves the cytoprotective effect of SNO-HSA in vivo, and reinforcement of an antiapoptotic effect by fatty acid binding contributes to this. Fatty acid bound to SNO-HSA enhances the interaction between SNO-HSA and HepG2 cells and the S-transnitrosation of SNO-HSA. This enhances NO transfer from SNO-HSA into the hepatocytes and the antiapoptotic effect. We found a novel filipin III-sensitive mechanism for the transfer of NO from SNO-HSA into hepatocytes. Taken together, further study is now warranted to explore the roles of fatty acid binding in the pharmacological benefits of SNO-HSA, for which clinical application is expected as a potent NO supplementary therapy as summarized in Figure 5 . 
